Zealand Pharma A/S (ZLDPF)

Zealand Pharma A/S (ZLDPF) Healthcare & Pipeline Overview

Zealand Pharma A/S is a Danish biotechnology firm focused on peptide-based medicines for gastrointestinal, metabolic, and specialty diseases. With a robust pipeline including two Phase III candidates and commercialized products, the company leverages strategic collaborations to address unmet medical needs within the global healthcare sector.

What Is the Investment Thesis for ZLDPF?

Zealand Pharma A/S presents a research thesis centered on its specialized expertise in peptide-based medicines, targeting high-value therapeutic areas with significant unmet medical needs. The company's advanced pipeline, featuring two distinct Phase III candidates—Dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome—represents potential near-term value inflection points. Successful clinical outcomes and subsequent regulatory approvals for these programs could unlock substantial market opportunities, given the limited treatment options for these conditions. Furthermore, Zealand Pharma benefits from existing commercialized products like lixisenatide (Adlyxin/Lyxumia) and Dasiglucagon for severe hypoglycemia, providing a foundation of revenue. Strategic collaborations with major pharmaceutical companies such as Sanofi-Aventis and Boehringer Ingelheim validate its scientific approach and provide critical resources for development and commercialization. Financially, the company demonstrates strong operational efficiency with a reported Profit Margin of 69.2% and an exceptional Gross Margin of 99.7%, alongside a substantial Free Cash Flow of $4.66 billion, indicating robust financial health and potential for sustained investment in its pipeline. The focus on specialty disease areas with high unmet needs positions Zealand Pharma for premium pricing and strong market penetration upon successful product launches.

Based on FMP financials and quantitative analysis

ZLDPF Key Highlights

• Zealand Pharma A/S commands a market capitalization of $3.23B, reflecting its standing as a significant player in the biotechnology sector.
• The company demonstrates strong profitability with a reported Profit Margin of 69.2%, indicating efficient management of its operations and cost structure.
• An exceptional Gross Margin of 99.7% highlights the high value and low direct cost associated with its peptide-based pharmaceutical products.
• Zealand Pharma A/S exhibits robust financial liquidity and operational efficiency with a Free Cash Flow (FCF) of $4.66 billion.
• The company's stock has a Beta of 0.56, suggesting lower volatility compared to the broader market, which may appeal to investors seeking relative stability within the biotechnology industry.

Who Are ZLDPF's Competitors?

ZLDPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ZLDPF's Key Strengths?

• Specialized expertise in peptide-based medicines with a strong R&D focus.
• Advanced clinical pipeline with two Phase III candidates addressing unmet medical needs.
• Strategic collaboration agreements with major global pharmaceutical companies.
• Existing portfolio of commercialized products providing current revenue streams.
• Strong financial metrics including high profit and gross margins, and substantial free cash flow.

What Are ZLDPF's Weaknesses?

• Reliance on successful outcomes of clinical trials, which inherently carry high risk.
• Limited geographic reach as a primary commercial entity, relying on partners for broader market access.
• Exposure to intense competition within the biotechnology and pharmaceutical sectors.
• Potential for regulatory delays or non-approvals for pipeline candidates.
• Operating in a niche market for rare diseases, which can have smaller patient populations.

What Could Drive ZLDPF Stock Higher?

• Results from Phase III clinical trials for Dasiglucagon in congenital hyperinsulinism, potentially leading to regulatory submission and approval.
• Readout of Phase III clinical trial data for glepaglutide in short bowel syndrome, a key step towards potential market authorization.
• Achievement of development or commercialization milestones under existing collaboration agreements with partners like Sanofi-Aventis and Boehringer Ingelheim, triggering payments.
• Potential regulatory approvals for new indications or geographic expansions of existing commercialized products such as lixisenatide or Dasiglucagon.
• Advancement of earlier-stage pipeline candidates into later clinical phases, demonstrating continued R&D productivity and future growth potential.

What Are the Key Risks for ZLDPF?

• Clinical trial failures for Dasiglucagon or glepaglutide, which would significantly impact the company's pipeline and future revenue prospects.
• Intense competition within the biotechnology sector for peptide-based medicines, potentially leading to market share erosion or pricing pressure.
• Regulatory hurdles or delays in obtaining approvals for new drugs or indications, extending development timelines and increasing costs.
• Dependence on collaboration partners for funding, development, and commercialization, exposing the company to partner-specific risks.
• Market acceptance challenges for new products, even upon approval, due to physician adoption rates, reimbursement issues, or competitive alternatives.

What Are the Growth Opportunities for ZLDPF?

• **Dasiglucagon for Congenital Hyperinsulinism (CHI) Approval:** Dasiglucagon is currently in Phase III clinical trials for congenital hyperinsulinism, a rare genetic disorder characterized by excessive insulin secretion and severe hypoglycemia. A successful outcome in these trials and subsequent regulatory approval would open a significant market opportunity in the orphan drug space. The global market for rare disease treatments is expanding, driven by high unmet needs and premium pricing potential. This approval could establish Dasiglucagon as a critical therapeutic option, providing a new revenue stream and addressing a life-threatening condition for which current treatments are often inadequate, potentially impacting thousands of patients worldwide.
• **Glepaglutide for Short Bowel Syndrome (SBS) Commercialization:** Glepaglutide, a long-acting GLP-2 analog, is also in Phase III clinical trials for the treatment of short bowel syndrome, a complex and debilitating condition often requiring parenteral nutrition. Successful development and commercialization of glepaglutide could significantly improve the quality of life for SBS patients by reducing the need for intravenous feeding and enhancing intestinal absorption. The market for SBS treatments, particularly those that offer long-acting benefits, represents a substantial opportunity, as patients seek therapies that minimize treatment burden. This product could capture a significant share of this specialized market upon approval.
• **Expansion of Commercialized Product Indications and Market Share:** Zealand Pharma's existing marketed products, lixisenatide (Adlyxin/Lyxumia) for type 2 diabetes and Dasiglucagon for severe hypoglycemia, offer ongoing growth potential. This includes exploring new indications for these established drugs, expanding their geographic reach through existing or new partnerships, and increasing market penetration within their current approved uses. For instance, Dasiglucagon's potential application in post-bariatric surgery hypoglycemia and as part of a dual-hormone artificial pancreas system could significantly broaden its addressable market and drive sustained revenue growth.
• **Leveraging Strategic Collaboration Agreements:** The company's robust network of collaboration agreements with major pharmaceutical entities like Sanofi-Aventis, Boehringer Ingelheim, Alexion Pharmaceuticals, and Beta Bionics represents a significant growth driver. These partnerships provide access to substantial funding, shared development expertise, and established global commercialization channels. Future milestones, expanded development programs, or new collaboration opportunities arising from these relationships could lead to increased royalty revenues, upfront payments, and accelerated pipeline progression, enhancing Zealand Pharma's market presence and financial performance.
• **Pipeline Diversification into Other Specialty Disease Areas:** Zealand Pharma A/S explicitly states its focus on "other specialty disease areas with unmet medical needs." This strategic pillar indicates a commitment to leveraging its peptide expertise to identify and develop novel therapies beyond its current disclosed pipeline. This could involve advancing earlier-stage programs, initiating new discovery efforts, or in-licensing promising candidates. Successfully identifying and developing treatments for additional high-value, niche indications would diversify the company's revenue streams, reduce reliance on a few key products, and solidify its position as a leader in peptide-based drug development for specialized conditions.

What Opportunities Does ZLDPF Have?

• Expansion into new therapeutic indications for existing and pipeline products.
• Further leveraging and expanding strategic partnerships for global commercialization and development.
• Potential for significant market penetration in orphan drug markets upon successful approvals.
• Advancements in drug delivery technologies for peptide-based therapies.
• Acquisition or in-licensing of complementary peptide technologies or pipeline assets.

What Threats Does ZLDPF Face?

• Clinical trial failures or unexpected safety concerns for pipeline candidates.
• Increased competition from new entrants or existing players developing similar therapies.
• Patent expirations or challenges to intellectual property rights.
• Adverse changes in healthcare policy, reimbursement landscapes, or regulatory requirements.
• Market acceptance issues for new products, even after regulatory approval.

What Are ZLDPF's Competitive Advantages?

• Specialized expertise in peptide-based drug discovery and development, a complex and high-barrier-to-entry field.
• Advanced clinical pipeline with two distinct Phase III candidates (Dasiglucagon for CHI, glepaglutide for SBS) addressing rare and unmet medical needs.
• Established commercialized products (lixisenatide, Dasiglucagon) providing existing revenue streams and market presence.
• Strategic collaborations with major global pharmaceutical companies, validating technology and providing access to resources and markets.
• Focus on orphan and specialty diseases, which often have less direct competition and higher pricing power upon approval.

What Does ZLDPF Do?

Zealand Pharma A/S, incorporated in 1998 and headquartered in Copenhagen, Denmark, is a biotechnology company dedicated to the discovery, development, and commercialization of innovative peptide-based medicines. The company's strategic focus is on addressing significant unmet medical needs within gastrointestinal and metabolic diseases, as well as other specialized therapeutic areas. Over its history, Zealand Pharma has evolved from a research-centric entity to a fully integrated biopharmaceutical company with both marketed products and a robust development pipeline. Its portfolio includes lixisenatide, marketed under the brand names Adlyxin and Lyxumia, which is used in the treatment of type 2 diabetes. Another key product is Dasiglucagon, available as a single-use syringe or autoinjector for the acute treatment of severe hypoglycemia, and also in development for congenital hyperinsulinism and post-bariatric surgery hypoglycemia. Furthermore, Dasiglucagon is being explored for use in a dual-hormone artificial pancreas system for automated diabetes management, showcasing the company's commitment to advanced therapeutic solutions. The company's late-stage pipeline features Dasiglucagon, currently in Phase III clinical trials for congenital hyperinsulinism, and glepaglutide, a long-acting GLP-2 analog, also in Phase III clinical trials for the treatment of short bowel syndrome. To enhance its global reach and development capabilities, Zealand Pharma A/S has established significant collaboration agreements with prominent pharmaceutical partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc. These partnerships are crucial for advancing its pipeline and commercializing its peptide-based therapies across various markets.

What Products and Services Does ZLDPF Offer?

• Discovers and develops peptide-based medicines.
• Focuses on treatments for gastrointestinal and metabolic diseases.
• Addresses other specialty disease areas with unmet medical needs.
• Markets lixisenatide (Adlyxin and Lyxumia) for type 2 diabetes.
• Provides Dasiglucagon for severe hypoglycemia, congenital hyperinsulinism, and post-bariatric surgery hypoglycemia.
• Develops Dasiglucagon for dual-hormone artificial pancreas for automated diabetes management.
• Advances glepaglutide (long-acting GLP-2 analog) for short bowel syndrome in Phase III trials.
• Engages in strategic collaboration agreements with major pharmaceutical companies for drug development and commercialization.

How Does ZLDPF Make Money?

• Generates revenue through sales of commercialized peptide-based medicines like lixisenatide and Dasiglucagon.
• Receives milestone payments and royalties from collaboration agreements with pharmaceutical partners for drug development and commercialization.
• Invests in research and development to discover and advance novel peptide candidates through clinical trials.
• Aims to address high-value, unmet medical needs in specialized disease areas to command premium pricing for its therapies.
• Leverages partnerships to share development costs, mitigate risks, and expand market access for its products globally.

What Industry Does ZLDPF Operate In?

Zealand Pharma A/S operates within the dynamic and innovation-driven biotechnology industry, specifically focusing on peptide-based medicines. This segment of the pharmaceutical market is characterized by high research and development costs, long development timelines, and significant regulatory hurdles, but also by the potential for substantial returns from novel therapies addressing unmet medical needs. The company's focus on gastrointestinal and metabolic diseases, including rare conditions like congenital hyperinsulinism and short bowel syndrome, places it in a specialized niche where competition, while intense, often targets specific patient populations. Market trends indicate a growing demand for targeted therapies and biologics, with peptides offering advantages in specificity and reduced side effects. Zealand Pharma competes with established pharmaceutical companies and other biotechnology firms developing similar therapeutic modalities. Its strategic collaborations with global pharmaceutical giants are crucial for navigating the competitive landscape, providing access to broader markets and shared development risks. The industry is also influenced by advancements in drug delivery systems and personalized medicine, areas where Zealand Pharma's dual-hormone artificial pancreas project aligns.

Who Are ZLDPF's Key Customers?

• Patients suffering from type 2 diabetes, severe hypoglycemia, congenital hyperinsulinism, and short bowel syndrome.
• Healthcare providers, including endocrinologists, gastroenterologists, and emergency medical personnel.
• Hospitals and clinics that administer treatments for metabolic and gastrointestinal disorders.
• Pharmaceutical companies through collaboration agreements for co-development and commercialization.
• Researchers and academic institutions through scientific partnerships.

Company Profile

Zealand Pharma A/S operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Copenhagen, DK. The company is led by CEO Adam Sinding Steensberg. ZLDPF has traded publicly since 2013.

How Zealand Pharma A/S Is Valued

Zealand Pharma A/S carries a market capitalization of $3.23B, placing it in the mid-cap category. Relative to its peer group, ZLDPF's quantitative score of 68/100 is above the peer average of 50/100.

ROE 43%Key Financial Metrics

Return on equity for Zealand Pharma A/S stands at 42.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 41.8%, showing how much profit it generates from its asset base. ZLDPF trades at a trailing price-to-earnings ratio of 3.13, below the Healthcare sector average of ~23x. Its free cash flow yield is 29.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 37.17 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 29.7%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 6/9Financial Health

Zealand Pharma A/S's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 18.79 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Zealand Pharma A/S revenue of about $4.61B for fiscal 2026, with EPS near $21.71. The estimate reflects 8 contributing analysts.

ZLDPF Financials

ZLDPF Latest News

ZLDPF Analyst Consensus

ZLDPF MoonshotScore

Common Questions About ZLDPF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources